The full 3rd US Circuit Court of Appeals on Monday, October 21, declined to reconsider a ruling that forced into arbitration an antitrust case by a drug wholesaler accusing Johnson & Johnson of suppressing competition for its blockbuster rheumatoid arthritis drug Remicade, reported Reuters.
The ruling, issued on September 13 by a three-judge panel, had overturned a 2018 decision by US District Judge Curtis Joyner in Philadelphia by holding that a broadly worded arbitration clause contained in the drug distribution contract Rochester Drug Cooperative (RDC) had with J&J covered its claims.
In its complaint, filed in 2018, RDC noted that, despite competition from biosimilars, J&J’s brand-name infliximab maintained and even increased its prices. “J&J did not achieve this unusual result by competition on the merits,” stated the complaint, “but instead through a multifaceted scheme to block biosimilar competition to Remicade through a web of exclusive dealing contracts.”
This case is just one of multiple cases related to J&J’s strategy to defend its market share for infliximab. In 2017, Pfizer filed an antitrust suit against J&J, alleging that the drug maker’s tactics had effectively denied patients access to biosimilar therapies (including Pfizer’s Inflectra) and undermined price competition in the biologics marketplace.
Full Content:
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google Wins Appeal Against EU’s €1.5 Billion Fine for Ad Monopoly Practices
Sep 18, 2024 by
CPI
Meta Introduces Teen Accounts to Address Growing Data Regulation Demands
Sep 17, 2024 by
CPI
FTC Lawyers Wrap Up Arguments to Block Kroger-Albertsons Merger
Sep 17, 2024 by
CPI
Financial Regulator to Monitor CNMC’s Ruling on BBVA-Sabadell Acquisition
Sep 17, 2024 by
CPI
Green Day Ticket Prices Spark Controversy Amid Dynamic Pricing Concerns
Sep 17, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Canada & Mexico
Sep 3, 2024 by
CPI
Competitive Convergence: Mexico’s 30-Year Quest for Antitrust Parity with its Northern Neighbor
Sep 3, 2024 by
Francisco Javier Núñez Melgoza
Competition and Digital Markets in North America: A Comparative Study of Antitrust Investigations in Mexico and the United States
Sep 3, 2024 by
Julio Garcia
Recent Antitrust Development in Mexico: COFECE’s Preliminary Report on Amazon and Mercado Libre
Sep 3, 2024 by
Alejandra Palacios Prieto
The Cost of Making COFECE Disappear
Sep 3, 2024 by
Mateo Fernández